8-K: Akoya Biosciences Secures $30 Million Convertible Note Financing from Quanterix Amidst Merger Agreement

Akoya Biosciences enters into a securities purchase agreement with Quanterix for up to $30 million in convertible notes, contingent on the ongoing merger agreement.

Summary

• Akoya Biosciences has entered into a securities purchase agreement with Quanterix Corporation.
• The agreement allows Akoya to issue and sell convertible promissory notes to Quanterix, totaling up to $30 million.
• Akoya can draw on these notes between May 15, 2025, and July 9, 2025, or potentially until January 9, 2026, depending on the status of the merger agreement between the two companies.
• The convertible notes will mature 91 days after the earlier of November 1, 2027, or the date Akoya's existing loan agreement with Midcap Financial Trust is fully repaid.
• The notes bear interest at SOFR plus a specified margin, payable monthly.
• Quanterix has the option to convert the notes into Akoya common stock if the merger agreement is terminated.
• The conversion price is based on the exchange ratio in the merger agreement and the VWAP of Quanterix's common stock prior to the merger agreement.
• Conversion is prohibited if it results in Quanterix holding more than 19.99% of Akoya's common stock without stockholder approval.
• Akoya will file a registration statement for the resale of shares issued upon conversion of the notes by August 13, 2025.
• A subordination agreement will be established, subordinating the convertible notes to Akoya's existing debt with MidCap Financial Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The financing provides Akoya with needed capital, but the terms are contingent on the merger and include certain restrictions. The agreement is a standard financial transaction in the context of a merger.

Positives

• Akoya gains access to a significant line of credit to support its operations and repay existing debt.
• The convertible nature of the notes provides flexibility for both Akoya and Quanterix.
• The financing provides Akoya with working capital pending the consummation of the merger agreement.
• The interest rate is tied to SOFR, a widely used benchmark, providing transparency.
• The agreement includes provisions for anti-dilution, protecting Quanterix's investment.

Negatives

• The financing is contingent on the status of the merger agreement, creating uncertainty.
• The conversion cap of 19.99% without stockholder approval may limit Quanterix's potential stake in Akoya.
• Akoya is obligated to file a registration statement, incurring additional expenses.
• The convertible notes are subordinate to Akoya's existing debt, potentially increasing risk for Quanterix.
• The agreement contains operating covenants that may restrict Akoya's actions until the merger is completed.

Risks

• The merger agreement may be terminated, impacting the terms and availability of the financing.
• Akoya may not be able to repay the convertible notes, leading to potential default.
• The value of Akoya's common stock may decline, reducing the value of the convertible notes.
• The market conditions may be unfavorable for the resale of shares issued upon conversion.
• The company may not be able to obtain stockholder approval for the conversion of the notes.

Future Outlook

The financing is intended to support Akoya's operations and repayment of existing debt, pending the potential completion of the merger with Quanterix. The terms of the financing are contingent on the status of the merger agreement.

Industry Context

This announcement reflects a trend of strategic financing in the biotech industry, where companies often seek capital to fund operations, research, and development, or to facilitate mergers and acquisitions. The use of convertible notes is a common financing mechanism, offering flexibility for both the issuer and the investor.

Comparison to Industry Standards

• Convertible note financing is a common practice in the biotech industry, especially for companies undergoing mergers or acquisitions.
• Comparable companies such as NanoString Technologies and Personalis have also utilized convertible notes to raise capital.
• The interest rates and conversion terms are generally in line with industry standards for similar transactions, reflecting the risk profile of the company and the market conditions.
• The subordination agreement is a standard provision in such financings, protecting the existing lenders' interests.

Related Party Transactions

• The securities purchase agreement between Akoya Biosciences and Quanterix Corporation is a related-party transaction, as it involves two companies that are parties to a merger agreement.

Stakeholder Impact

• Shareholders: The financing may dilute existing shareholders if the convertible notes are converted into common stock.
• Employees: The financing provides financial stability for Akoya, potentially securing jobs.
• Customers: The financing supports Akoya's ability to continue providing products and services.
• Creditors: The subordination agreement protects the interests of existing lenders.
• Suppliers: The financing ensures Akoya can continue to meet its financial obligations to suppliers.

Next Steps

• Akoya will draw on the convertible notes between May 15, 2025, and July 9, 2025, or potentially until January 9, 2026, depending on the status of the merger agreement.
• Akoya will file a registration statement for the resale of shares issued upon conversion of the notes by August 13, 2025.
• Quanterix will decide whether to convert the notes into Akoya common stock if the merger agreement is terminated.
• Akoya will seek stockholder approval for the conversion of the notes if required to exceed the 19.99% ownership cap.

Key Dates

Keywords

convertible notes, securities purchase agreement, Akoya Biosciences, Quanterix Corporation, merger agreement, financing, subordination agreement, registration rights, SOFR, common stock